May 14, 2019

Edward Kaye
Chief Executive Officer
Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford, MA 01730

       Re: Stoke Therapeutics, Inc.
           Amendment No. 1 to Draft Registration Statement on Form S-1
           Submitted April 30, 2019
           CIK No. 0001623526

Dear Dr. Kaye:

      We have reviewed your amended draft registration statement and have the
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

       After reviewing the information you provide in response to these
comments and your
amended draft registration statement or filed registration statement, we may
have additional
comments. Unless we note otherwise, our references to prior comments are to
comments in our
April 17, 2019 letter.

Amendment No. 1 to Draft Registration Statement on Form S-1

Prospectus summary
Company overview, page 1

1.     Please balance your statement that you believe you have the first
genetic medicine with
       the potential to significantly reduce the occurrence of seizures for
Dravet syndrome
       patients and to address the severe intellectual and developmental
disabilities of the disease
       by clarifying here that you are in an early stage of your development
and that to date you
       have only conducted preclinical studies for your product candidate.
 Edward Kaye
Stoke Therapeutics, Inc.
May 14, 2019
Page 2
STK-001: Preclinical data, page 100

2.       Please disclose how many groups of pre-pubescent monkeys were
administered with a
         single dose of STK-001 and how many control groups you used in the
preclinical study
         described on page 103.
Description of capital stock
Anti-takeover provisions
Restated certificate of incorporation and restated bylaw provisions, page 147

3.       We continue to consider your response to our prior comment 8. Please
note that we may
         have additional comments.
Notes to Consolidated Financial Statements
8. Convertible preferred stock
Liquidation, page F-18, page F-18

4.       Please demonstrate to us why you believe that common shareholders hold
a majority of
         the board seats and, as such, that the company controls the vote of
the Board of Directors
         and any deemed liquidation event. As of December 31, 2018, it appears
that only two
         board seats elected are controlled by common shareholders. In this
regard, it appears that
         pursuant to articles 3.2.3 and 3.2.4 of your certificate of
incorporation (exhibit 3.1) that
         the other four board seats elected are controlled by the preferred
shareholders or
         effectively controlled by preferred shareholders voting together with
common stock as a
         single class given the number of shares of preferred entitled to vote
on an as-converted
       You may contact Rolf Sundwall at 202-551-3105 or Jim Rosenberg at
202-551-3679 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Sonia Bednarowski at 202-551-3666 or Justin Dobbie at 202-551-3469 with
any other

FirstName LastNameEdward Kaye                                  Sincerely,
Comapany NameStoke Therapeutics, Inc.
                                                               Division of
Corporation Finance
May 14, 2019 Page 2                                            Office of
Healthcare & Insurance
FirstName LastName